<DOC>
	<DOCNO>NCT00958971</DOCNO>
	<brief_summary>The purpose trial determine efficacy safety profile TKI258 4 group patient metastatic HER2 negative breast cancer ( BC ) stratify FGFR1 hormone receptor ( HR ) status .</brief_summary>
	<brief_title>Safety Efficacy TKI258 FGFR1 Amplified Non-amplified Metastatic HER2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Female present metastatic breast cancer . 2 . Tumor must test FISH/CISH FGFR1 amplification . 3 . HER2 HR status must determine . 4 . Patients must HER2 negative breast cancer . 5 . Patients must document disease progression define RECIST baseline . 6 . Patients HR+ disease : Must receive least one prior endocrine therapy metastatic setting . Must receive three line chemotherapy metastatic setting . 7 . Patients HR disease must receive least one three line chemotherapy metastatic setting . 1 . Patients know brain metastasis signs/symptoms attributable brain metastasis assess radiologic imaging rule presence brain metastasis . 2 . Impaired cardiac function clinically significant cardiac disease , include follow : History presence serious uncontrolled ventricular arrhythmia presence atrial fibrillation . Clinically significant rest bradycardia ( &lt; 50 beat per minute ) . LVEF assess 2D echocardiogram ( ECHO ) Multiple gated acquisition scan ( MUGA ) &lt; 45 % . 3 . Any follow within 6 month prior study entry : myocardial infarction ( MI ) , severe/unstable angina , Coronary Artery Bypass Graft ( CABG ) , Congestive Heart Failure ( CHF ) , Cerebrovascular Accident ( CVA ) , Transient Ischemic Attack ( TIA ) , Pulmonary Embolism ( PE ) . 4 . Uncontrolled hypertension define SBP &gt; 150mm Hg and/or DBP &gt; 100mm Hg , without antihypertensive medication . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>FGFR1</keyword>
</DOC>